GlaxoSmithKline (GSK) Given a GBX 1,300 Price Target at Credit Suisse Group

GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,300 ($18.23) price target by stock analysts at Credit Suisse Group in a research report issued on Thursday. The firm currently has a “neutral” rating on the stock. Credit Suisse Group’s price target indicates a potential upside of 0.70% from the company’s current price.

Several other equities research analysts also recently commented on GSK. UBS Group set a GBX 1,600 ($22.43) target price on GlaxoSmithKline and gave the company a “neutral” rating in a report on Monday, October 23rd. Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($25.24) target price on shares of GlaxoSmithKline in a report on Monday, October 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,570 ($22.01) target price on shares of GlaxoSmithKline in a report on Monday, October 23rd. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a report on Monday, October 23rd. Finally, Goldman Sachs Group reiterated a “buy” rating and set a GBX 1,900 ($26.64) target price on shares of GlaxoSmithKline in a report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of GBX 1,541.36 ($21.61).

GlaxoSmithKline (LON:GSK) traded down GBX 12.80 ($0.18) during midday trading on Thursday, hitting GBX 1,291 ($18.10). The stock had a trading volume of 11,680,000 shares, compared to its average volume of 9,480,000. The firm has a market cap of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.32) and a fifty-two week high of GBX 1,724.50 ($24.18).

In other GlaxoSmithKline news, insider Sir Roy Anderson purchased 562 shares of GlaxoSmithKline stock in a transaction on Wednesday, February 7th. The stock was bought at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). Insiders have purchased a total of 581 shares of company stock valued at $743,284 in the last 90 days.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline (GSK) Given a GBX 1,300 Price Target at Credit Suisse Group” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/11/glaxosmithkline-gsk-given-a-gbx-1300-price-target-at-credit-suisse-group.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply